Burns
Conditions
Brief summary
The overall purpose of this continued access study is to allow ongoing treatment of subjects at selected investigational sites while the marketing application for the ReCell® Autologous Cell Harvesting Device is under FDA review. This is a prospective, multicenter, single-arm observational study to evaluate the safety and clinical performance of the ReCell® device when used as an adjunct to meshed autografts in patients with acute thermal burn injuries requiring skin grafting for closure.
Detailed description
Patients 5 years or older with a total body surface area (TBSA) thermal burn injury between 5 and 50% (inclusive) who require autografting will be considered for participation in this study. RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting. Healing, scar outcomes, pain and treatment-related adverse events will be evaluated at follow-up visits. Data concerning the clinical performance and safety of the ReCell device will be collected. Safety will be evaluated in terms of treatment and serious related adverse events. Each subject will participate in up to 7 total visits (treatment visit and 6 follow-up study visits) over a period of 24 weeks. Up to 60 subjects will be enrolled and treated within this study at up to 15 institutions. It is anticipated that enrollment will continue until PMA approval. Subject follow-up will continue until the last enrolled subject completes the 24-week visit.
Interventions
RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
Sponsors
Advanced Clinical Research Services, LLC
Avita Medical
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The subject requires skin grafting as a result of an acute thermal burn injury (i.e., injuries caused by exposure of the skin to fire/flames, excessive heat, hot steam or water). 2. The area of total burn injury is 5-50% TBSA inclusive. 3. Area(s) requiring skin grafting at least 320 square centimeters. 4. The subject is at least 5 years of age. 5. The subject (or family, for those under 18 years of age) is willing and able to complete all follow-up evaluations required by the study protocol. 6. The subject is to abstain from any other treatment of the wound(s) for the duration of the study unless medically necessary. 7. The subject agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study. 8. The subject and/or guardian are able to read and understand instructions and give informed, voluntary, written consent.
Exclusion criteria
1. The subject's burn injuries were caused by chemicals, electricity, and/or radioactive substances. 2. The subject is unable to follow the protocol. 3. The subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives. 4. The subject has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann's) solution. 5. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Wound Healing | Confirmed by week 8, at two consecutive study visits at least 2 weeks apart up to 24 Weeks (e.g., at week 4 and week 8, or if a visit was missed, week 4 and week 12) | Treatment area will be evaluated via direct visualization by the treating investigator. Complete wound closure is defined as ≥95 to100% re-epithelialization without drainage by week 8. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| RES (Regenerative Epithelial Suspension) ReCell® Autologous Cell Harvesting Device: RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting. | 76 |
| Total | 76 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Death | 2 |
| Overall Study | Lost to Follow-up | 10 |
Baseline characteristics
| Characteristic | RES (Regenerative Epithelial Suspension) |
|---|---|
| Age, Categorical <=18 years | 10 Participants |
| Age, Categorical >=65 years | 12 Participants |
| Age, Categorical Between 18 and 65 years | 54 Participants |
| Age, Continuous | 43.8 years STANDARD_DEVIATION 20.45 |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 20 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants |
| Race (NIH/OMB) White | 49 Participants |
| Region of Enrollment United States | 76 participants |
| Sex: Female, Male Female | 25 Participants |
| Sex: Female, Male Male | 51 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 76 |
| other Total, other adverse events | 39 / 76 |
| serious Total, serious adverse events | 16 / 76 |
Outcome results
Primary
Percentage of Participants With Wound Healing
Treatment area will be evaluated via direct visualization by the treating investigator. Complete wound closure is defined as ≥95 to100% re-epithelialization without drainage by week 8.
Time frame: Confirmed by week 8, at two consecutive study visits at least 2 weeks apart up to 24 Weeks (e.g., at week 4 and week 8, or if a visit was missed, week 4 and week 12)
Population: Per Protocol
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| RES (Regenerative Epithelial Suspension) | Percentage of Participants With Wound Healing | 95.3 percentage of participants |